97 related articles for article (PubMed ID: 24974831)
1. Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinib-resistant lung cancer growth.
Jung SK; Lee MH; Lim DY; Lee SY; Jeong CH; Kim JE; Lim TG; Chen H; Bode AM; Lee HJ; Lee KW; Dong Z
Mol Carcinog; 2015 Apr; 54(4):322-31. PubMed ID: 24974831
[TBL] [Abstract][Full Text] [Related]
2. YES1 as a potential target to overcome drug resistance in EGFR-deregulated non-small cell lung cancer.
Kook E; Lee J; Kim DH
Arch Toxicol; 2024 May; 98(5):1437-1455. PubMed ID: 38443724
[TBL] [Abstract][Full Text] [Related]
3. Single targeting of MET in EGFR-mutated and MET-amplified non-small cell lung cancer.
Choi YR; Kang EH; Kim S; Park SY; Han JY; Lee Y
Br J Cancer; 2023 Jun; 128(12):2186-2196. PubMed ID: 37059804
[TBL] [Abstract][Full Text] [Related]
4. The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents.
Robinson KW; Sandler AB
Oncologist; 2013; 18(2):115-22. PubMed ID: 23345546
[TBL] [Abstract][Full Text] [Related]
5.
Pool M; Terwisscha van Scheltinga AGT; Kol A; Giesen D; de Vries EGE; Lub-de Hooge MN
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1328-1336. PubMed ID: 28315949
[TBL] [Abstract][Full Text] [Related]
6. Integrative Analysis of Proteome and Ubiquitylome Reveals Unique Features of Lysosomal and Endocytic Pathways in Gefitinib-Resistant Non-Small Cell Lung Cancer Cells.
Li W; Wang H; Yang Y; Zhao T; Zhang Z; Tian Y; Shi Z; Peng X; Li F; Feng Y; Zhang L; Jiang G; Zhang F
Proteomics; 2018 Aug; 18(15):e1700388. PubMed ID: 29901268
[TBL] [Abstract][Full Text] [Related]
7. MET as a possible target for non-small-cell lung cancer.
Sadiq AA; Salgia R
J Clin Oncol; 2013 Mar; 31(8):1089-96. PubMed ID: 23401458
[TBL] [Abstract][Full Text] [Related]
8. Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
Drilon A; Cappuzzo F; Ou SI; Camidge DR
J Thorac Oncol; 2017 Jan; 12(1):15-26. PubMed ID: 27794501
[TBL] [Abstract][Full Text] [Related]
9. Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments.
Li K; Tavaré R; Zettlitz KA; Mumenthaler SM; Mallick P; Zhou Y; Marks JD; Wu AM
Mol Cancer Ther; 2014 Nov; 13(11):2607-17. PubMed ID: 25143449
[TBL] [Abstract][Full Text] [Related]
10. USP24-i-101 targeting of USP24 activates autophagy to inhibit drug resistance acquired during cancer therapy.
Young MJ; Wang SA; Chen YC; Liu CY; Hsu KC; Tang SW; Tseng YL; Wang YC; Lin SM; Hung JJ
Cell Death Differ; 2024 May; 31(5):574-591. PubMed ID: 38491202
[TBL] [Abstract][Full Text] [Related]
11. Sensitizing drug-resistant cancer cells from blood using microfluidic electroporator.
Sung HW; Choi SE; Chu CH; Ouyang M; Kalyan S; Scott N; Hur SC
PLoS One; 2022; 17(3):e0264907. PubMed ID: 35259174
[TBL] [Abstract][Full Text] [Related]
12. Butein inhibits oral squamous cell carcinoma growth via promoting MCL-1 ubiquitination.
Wang R; Li X; Wang J
J Cancer; 2024; 15(10):3173-3182. PubMed ID: 38706892
[TBL] [Abstract][Full Text] [Related]
13. Exploiting
Di Noia V; D'Argento E; Pilotto S; Ferrara MG; Milella M; Tortora G; Bria E
Transl Lung Cancer Res; 2018 Dec; 7(Suppl 4):S312-S317. PubMed ID: 30705843
[No Abstract] [Full Text] [Related]
14. Isoliquiritigenin induces apoptosis and inhibits xenograft tumor growth of human lung cancer cells by targeting both wild type and L858R/T790M mutant EGFR.
Jung SK; Lee MH; Lim DY; Kim JE; Singh P; Lee SY; Jeong CH; Lim TG; Chen H; Chi YI; Kundu JK; Lee NH; Lee CC; Cho YY; Bode AM; Lee KW; Dong Z
J Biol Chem; 2014 Dec; 289(52):35839-48. PubMed ID: 25368326
[TBL] [Abstract][Full Text] [Related]
15. The daidzein metabolite, 6,7,4'-Trihydroxyisoflavone, is a novel inhibitor of PKCα in suppressing solar UV-induced matrix metalloproteinase 1.
Lim TG; Kim JE; Lee SY; Park JS; Yeom MH; Chen H; Bode AM; Dong Z; Lee KW
Int J Mol Sci; 2014 Nov; 15(11):21419-32. PubMed ID: 25415304
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplification.
Jang WJ; Jung SK; Kang JS; Jeong JW; Bae MK; Joo SH; Park GH; Kundu JK; Hong YS; Jeong CH
Cancer Sci; 2014 Oct; 105(10):1245-53. PubMed ID: 25117641
[TBL] [Abstract][Full Text] [Related]
17. 20-O-β-D-glucopyranosyl-20(S)-protopanaxadiol, a metabolite of ginsenoside Rb1, enhances the production of hyaluronic acid through the activation of ERK and Akt mediated by Src tyrosin kinase in human keratinocytes.
Lim TG; Jeon AJ; Yoon JH; Song D; Kim JE; Kwon JY; Kim JR; Kang NJ; Park JS; Yeom MH; Oh DK; Lim Y; Lee CC; Lee CY; Lee KW
Int J Mol Med; 2015 May; 35(5):1388-94. PubMed ID: 25738334
[TBL] [Abstract][Full Text] [Related]
18. The ginsenoside 20-O-β-D-glucopyranosyl-20(S)-protopanaxadiol induces autophagy and apoptosis in human melanoma via AMPK/JNK phosphorylation.
Kang S; Kim JE; Song NR; Jung SK; Lee MH; Park JS; Yeom MH; Bode AM; Dong Z; Lee KW
PLoS One; 2014; 9(8):e104305. PubMed ID: 25137374
[TBL] [Abstract][Full Text] [Related]
19. c-Met targeting in advanced gastric cancer: An open challenge.
Marano L; Chiari R; Fabozzi A; De Vita F; Boccardi V; Roviello G; Petrioli R; Marrelli D; Roviello F; Patriti A
Cancer Lett; 2015 Aug; 365(1):30-6. PubMed ID: 26049023
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of c-Met in breast cancer: a meta-analysis of 6010 cases.
Yan S; Jiao X; Zou H; Li K
Diagn Pathol; 2015 Jun; 10():62. PubMed ID: 26047809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
